By targeting multiple components of the Wnt, Nodal/Activin, BMP, MAPK, and PI3K/AKT pathways, these tumor-suppressive miRNAs promote PCSC differentiation, sensitize cells to gemcitabine, and reduce tumor volume. The gene discussed is AKT1; the disease is neoplasm.